Synthetic biology — a discipline derived from the convergence of biotechnology, genetic engineering, systems biology and more — is ready for its time in the sun.
Despite being a young field, beginning in earnest in the late 1990s, synthetic biology already has a significant effect on the way we live. It has given us biofuels, degradable plastics and — for better or worse — algae butter. With the advent of the Crispr-Cas9 system in 2012, it has become cheaper and easier than ever to manipulate DNA and construct artificial biological systems.
Gene therapy
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze